Notice Number: NOT-OD-16-113
Key Dates
Release Date: June 16, 2016
Issued by
Department of Health and Human Services (DHHS)
Purpose
Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:
Meredyth M. Forbes, Albert Einstein College of Medicine: Based on an assessment conducted by the Albert Einstein College of Medicine (AECM), an admission from the Respondent, and additional analysis conducted by ORI in its oversight review, ORI found that Ms. Meredyth M. Forbes, former Graduate Student, AECM, engaged in research misconduct in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grants R01 GM089979, T32 GM007491, R01 GM55101, and R01 GM88202 and National Institute of Child Health and Human Development (NICHD), NIH, grant T32 HD007502.
ORI found that Respondent engaged in research misconduct by intentionally falsifying and/or fabricating data reported in the following three (3) published papers and four (4) meeting presentations:
ORI found that Respondent intentionally falsified and/or fabricated data for germ-cell development in zebrafish Dazap2 maternal-effect mutants (MDazap2) in one (1) paper and two (2) presentations when the mutants were not produced nor the data derived from them.
Specifically, Respondent:
ORI found that Respondent intentionally fabricated and/or falsified data for zebrafish embryogenesis and oocyte polarity in two (2) papers and two (2) presentations when the data were not obtained from actual experiments.
Specifically, Respondent:
Ms. Forbes has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on May 6, 2016:
(1) to exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS' Implementation (2 CFR part 376 et seq.) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively
the “Debarment Regulations”);
(2) that she will neither apply for nor permit her name to be used on any application, proposal, or other request for funds to the United States Government or any of its agencies, as defined in the Debarment Regulations; Respondent will further ensure that during the period of the voluntary exclusion, she will neither receive nor be supported by funds of the United States Government and its agencies made available through grants, subgrants, cooperative agreements, contracts, or
subcontracts, as discussed in the Debarment Regulations; and
(3) to exclude herself from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.
Inquiries
Please direct all inquiries to:
FOR FURTHER INFORMATION CONTACT:
Kathryn M. Partin
Director
Office of Research Integrity
1101 Wootton Parkway, Suite 750
Rockville, MD 20852
(240) 453-8800